MBQ-167 is a potent inhibitor of the interaction between the proteins CDC42 and IQGAP1, which plays a key role in cancer cell signaling, migration, and invasion. It is primarily investigated for its anti-cancer properties, especially in aggressive and metastatic cancers. Studies show that MBQ-167 effectively reduces tumor growth and metastasis in models of breast and prostate cancer by disrupting pathways involved in cell proliferation and motility. Because it targets specific protein-protein interactions involved in cancer progression, MBQ-167 represents a promising candidate for targeted cancer therapy, particularly in tumors resistant to conventional treatments. Its ability to inhibit both tumor growth and spread makes it a focus in the development of novel oncology drugs.